Compare SKY & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | FOLD |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 1994 | 2006 |
| Metric | SKY | FOLD |
|---|---|---|
| Price | $82.01 | $14.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $98.50 | $27.25 |
| AVG Volume (30 Days) | 416.9K | ★ 2.3M |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.18 | ★ 50.00 |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $2,483,448,000.00 | N/A |
| Revenue This Year | $7.79 | $20.50 |
| Revenue Next Year | $3.10 | $18.59 |
| P/E Ratio | $25.95 | ★ N/A |
| Revenue Growth | ★ 22.65 | N/A |
| 52 Week Low | $59.44 | $5.66 |
| 52 Week High | $99.17 | $14.48 |
| Indicator | SKY | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 74.18 |
| Support Level | $72.93 | $14.21 |
| Resistance Level | $86.42 | N/A |
| Average True Range (ATR) | 2.52 | 0.02 |
| MACD | 0.91 | -0.00 |
| Stochastic Oscillator | 79.80 | 100.00 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business with 72 retail locations across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several dispatch locations across the United States.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.